Dr. Sharvil Patel
#106Managing Director
46
Age
21y
Exp
21y
Tenure
7/10
Risk
🎓 Specialisation in Chemical and Pharmaceutical Sciences · University of Sunderland
📜 Doctorate (PhD) · University of Sunderland
🏛️ None
CompensationTBP
Personality
7
Open
7
Cons
5
Extr
6
Agre
3
Neur
Zydus Lifesci.
Healthcare · Large Cap
High Growth · Innovation-Led
About
Dr. Sharvil Patel is the Managing Director of Zydus Lifesci., a Large Cap company in the Healthcare sector with a market cap of ₹91K Cr. A Visionary leader with 21 years of experience, he is known for data-driven decision-making and organic builder strategy. His focus on high-risk R&D and complex specialty generics demonstrates a clear appetite for innovation-led growth.
FAQ
What is Dr. Sharvil Patel's leadership style?
Dr. Sharvil Patel is classified as a Visionary leader. He is data-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Dr. Sharvil Patel's educational background?
Dr. Sharvil Patel holds a Specialisation in Chemical and Pharmaceutical Sciences from University of Sunderland and a Doctorate (PhD) from University of Sunderland.
Who is the CEO of Zydus Lifesci.?
Dr. Sharvil Patel is the Managing Director of Zydus Lifesci.. He has been with the company for 21 years and in the current role for 8 years.
Leadership DNA
ArchetypeVisionary
MotivationCategory Creator
CrisisRestructurer
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTrusted
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“His focus on high-risk R&D and complex specialty generics demonstrates a clear appetite for innovation-led growth.”
⚡ Crisis●●●●○
He led the strategic rebranding and organizational restructuring of Cadila Healthcare into Zydus Lifesciences to sharpen focus on specialty and innovation-led portfolios.
🎯 Motivation●●●●○
He has aggressively pivoted the company toward complex generics, biosimilars, and novel drug discovery, aiming to define Zydus's position in high-barrier specialty segments.
👥 People●●●○○
His leadership style is characterized by a high-intensity, data-driven approach to R&D outcomes and operational efficiency metrics.
📈 Growth●●●●○
Zydus's growth under his tenure has been primarily driven by massive internal R&D investment and scaling of in-house manufacturing capabilities for complex molecules.
💡 Innovation●●●●○
The company excels at building complex generic pipelines and biosimilars, leveraging strong R&D to scale products once patent barriers are cleared.
🏃 Pace●●●●○
The company maintains a consistent, methodical rhythm of regulatory filings and capacity expansion typical of a large-cap pharmaceutical firm.
🌱 Purpose●●●●○
The Zydus Foundation actively integrates healthcare access and community wellness initiatives into their long-term corporate strategy.
🏷️ Brand●●●●○
With a legacy spanning decades, the brand is defined by its institutional reliability and consistent delivery of essential medicines to the healthcare ecosystem.
🤝 Customer●●●●●
The core business model relies on supplying pharmaceutical products to hospitals, distributors, and global retail pharmacy chains rather than direct-to-consumer retail.
💼 Employer●●●○○
The company is recognized for its robust technical training and R&D exposure, often serving as a foundational career step for pharmaceutical scientists.
📋 Mandate
Transitioning from generic manufacturing to complex specialty generics and novel drug discovery requires a leader focused on R&D-led growth.
🏢 Culture●●●●○
Heavy investment in R&D and focus on complex generics signifies a culture built around scientific product innovation.
Financials
Revenue FY25₹23K Cr
PAT FY25₹5K Cr
Rev CAGR 5Y15%
OPM26.5%
NPM20%
ROE18.9%
ROCE21.2%
P/E18.5
Fwd P/E21.8
P/B3.6
D/E34.3
Promoter75.2%
Institutional14.9%
Mkt Cap₹91K Cr
Compensation
To Be Published
Data being verified from audited reports
